Product
Mezigdomide
Aliases
BMS986348, BMS 986348, BMS-986348, CC 92480, CC-92480 (5 other aliases)
9 clinical trials
3 indications
Indication
Renal ImpairmentIndication
Liver ImpairmentIndication
Multiple MyelomaClinical trial
A Phase 1, Multi-center, Open-label, Single-dose Study to Assess the Pharmacokinetics of Mezigdomide (BMS-986348, CC-92480) in Adult Participants With Normal Renal Function, Severe Renal Impairment, and End-stage Renal DiseaseStatus: Not yet recruiting, Estimated PCD: 2025-03-05
Clinical trial
A Phase 1, Multicenter, Open-label, Single-dose Study to Assess the Pharmacokinetics of Mezigdomide in Healthy Participants and Those With Mild, Moderate, and Severe Hepatic ImpairmentStatus: Completed, Estimated PCD: 2023-09-13
Clinical trial
A Phase 1, Multicenter, Open-label Study to Evaluate the Safety and Preliminary Efficacy of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma and Determine the Recommended Dose for Each Add-on Investigational ComponentStatus: Recruiting, Estimated PCD: 2028-08-01
Clinical trial
A Phase 1b/2a, Multicenter, Open-label Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple MyelomaStatus: Recruiting, Estimated PCD: 2032-02-13
Clinical trial
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination With Backbone Treatments for Relapsed/Refractory Multiple Myeloma and Newly Diagnosed Multiple MyelomaStatus: Active (not recruiting), Estimated PCD: 2027-04-01
Clinical trial
Phase I/II Trial of Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple MyelomaStatus: Recruiting, Estimated PCD: 2026-10-01
Clinical trial
Phase 1b Study to Assess Safety and Efficacy of Elotuzumab, CC-92480, and Dexamethasone in Relapsed/Refractory Myeloma After CD38- and BCMA-Targeted TherapiesStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Phase 3, Two-stage, Randomized, Multicenter, Open-label Study Comparing Mezigdomide (CC-92480/BMS-986348), Carfilzomib, and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM): SUCCESSOR-2Status: Recruiting, Estimated PCD: 2026-02-04
Clinical trial
A Phase 1 Study of Mezigdomide (CC-92480) and Dexamethasone Post Idecabtagene Vicleucel in Relapsed Multiple MyelomaStatus: Recruiting, Estimated PCD: 2026-03-21